|
| 10466. THE U.S. PHARMACEUTICAL INDUSTRY AND OLIGOPOLY. Argues that while the domestic ethical (prescription) drug industry is an oligopoly, this has largely been the result of patent protection and FDA regulation. Examines concentration ratios, history of industry, economies of scale, price fixing, product life cycles, R&D costs and trends, effects of early 1960s Kefauver hearings and subsequent regulation and its eventual reform in the 1980s, how R&D has moved overseas, role of advertising & promotion, legal risks (lawsuits, etc.), patent protection, competition from generic and counterfeit drugs, conclusions. 27p., 117f, 40b. |
|
$133
|
|
 |